CONNECT BIOPHARMA HOLDINGS L (CNTB) Forecast, Price Target & Analyst Ratings

NASDAQ:CNTB • KYG235491019

Current stock price

2.53 USD
+0.13 (+5.42%)
At close:
2.53 USD
0 (0%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CONNECT BIOPHARMA HOLDINGS L (CNTB).

Forecast Snapshot

Consensus Price Target

Price Target
$8.54
+ 237.65% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 18, 2026
Period
Q1 / 2026
EPS Estimate
-$1.44
Revenue Estimate
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
85.45%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$8.54
Upside
+ 237.65%
From current price of $2.53 to mean target of $8.54, Based on 11 analyst forecasts
Low
$7.07
Median
$8.42
High
$10.50

Price Target Revisions

1 Month
6.01%
3 Months
6.01%

Price Target Summary

11 Wall Street analysts provided a forecast for the next 12 months for CNTB. The average price target is 8.54 USD. This implies a price increase of 237.65% is expected in the next year compared to the current price of 2.53.
The average price target has been revised upward by 6.01% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

CNTB Current Analyst RatingCNTB Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 1 2 3 4 5

Analyst Ratings History

CNTB Historical Analyst RatingsCNTB Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8 10

Analyst Ratings Consensus

ChartMill Buy Consensus
85.45%
CNTB was analyzed by 11 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about CNTB.
In the previous month the buy percentage consensus was at a similar level.
CNTB was analyzed by 11 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-04-01BTIGReiterate Buy -> Buy
2026-03-31BTIGReiterate Buy -> Buy
2025-12-01Lake StreetInitiate Buy
2025-11-13BTIGReiterate Buy -> Buy
2025-10-31BTIGInitiate Buy
2025-08-13HC Wainwright & Co.Reiterate Buy -> Buy
2025-04-01HC Wainwright & Co.Reiterate Buy -> Buy
2025-03-31HC Wainwright & Co.Reiterate Buy -> Buy
2024-09-06HC Wainwright & Co.Reiterate Buy -> Buy
2024-06-13HC Wainwright & Co.Reiterate Buy -> Buy
2024-04-17HC Wainwright & Co.Maintains Buy -> Buy
2024-03-04HC Wainwright & Co.Initiate Buy
2023-09-13Cantor FitzgeraldReiterate Overweight -> Overweight
2023-02-08SVB LeerinkMaintains Outperform
2022-06-02Cantor FitzgeraldInitiate Overweight
2022-05-05Piper SandlerDowngrade Overweight -> Neutral
2022-05-04SVB LeerinkMaintains Outperform
2022-01-06SVB LeerinkMaintains Outperform
2021-07-02CICCInitiate Outperform
2021-04-13SVB LeerinkInitiate Outperform
2021-04-13JefferiesInitiate Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 18, 2026
Period
Q1 / 2026
EPS Estimate
-$1.44
Revenue Estimate
Revenue Q2Q
N/A
EPS Q2Q
-655.68%
Number of Analysts
6

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
-20.73%
EPS (3 Months)
-339.88%

Next Earnings Summary

CNTB is expected to report earnings on 5/18/2026. The consensus EPS estimate for the next earnings is -1.44 USD and the consensus revenue estimate is 0 USD.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
CNTB revenue by date.CNTB revenue by date.
26.033M64K
-99.75%
-100.00%		97.523M166.13M
70.35%		64.377M
-61.25%		86.165M
33.84%		215.47M
150.07%		281.68M
30.73%		352.28M
25.06%
EBITDA
YoY % growth
CNTB ebitda by date.CNTB ebitda by date.
-71.202M
90.84%		-19.792M
72.20%		-57.37M
-189.86%		N/AN/AN/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
CNTB ebit by date.CNTB ebit by date.
-71.931M
90.83%		-20.452M
71.57%		-58.074M
-183.95%		-280.97M
-383.81%		-261.337M
6.99%		-67.304M
74.25%		-37.544M
44.22%		1.632M
104.35%		46.726M
2,763.11%		98.043M
109.83%		150.99M
54.00%
Operating Margin
CNTB operating margin by date.CNTB operating margin by date.
N/A-78.56%-90,740.63%N/A-267.98%-40.51%-58.32%1.89%21.69%34.81%42.86%
EPS
YoY % growth
CNTB eps by date.CNTB eps by date.
N/A
59.72%		N/A
73.94%		-2.64
-67.99%		-4.18
-58.23%		-3.64
12.99%		-5.30
-45.69%		-0.51
90.38%		-0.40
22.00%		0.29
171.79%		0.71
150.00%		1.15
61.43%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth		-1.44
-655.68%		-1.36
-492.55%		-1.29
-316.94%		-0.84
56.24%		-0.28
80.82%		-0.28
79.79%		-0.28
78.69%		-0.29
65.90%
Revenue
Q2Q % growth
-100.00%
-100.00%		52.77MN/AN/AN/AN/A
EBITDA
Q2Q % growth		N/AN/AN/AN/AN/AN/AN/AN/A
EBIT
Q2Q % growth		-88.788M
9.88%		-90.267M
-572.43%		-87.703M
-396.14%		-60.279M
-288.25%		N/AN/AN/AN/A

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

CNTB Yearly Revenue VS EstimatesCNTB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M
CNTB Yearly EPS VS EstimatesCNTB Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -5 -10 -15 -20 -25

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
-26.11%
EPS Next 5 Year
13.09%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
716.20%
Revenue Next 5 Year
209.07%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

CONNECT BIOPHARMA HOLDINGS L / CNTB Forecast FAQ

What do analysts expect the price target to be for CONNECT BIOPHARMA HOLDINGS L (CNTB)?

11 analysts have analysed CNTB and the average price target is 8.54 USD. This implies a price increase of 237.65% is expected in the next year compared to the current price of 2.53.

What is the next earnings date for CNTB stock?

CONNECT BIOPHARMA HOLDINGS L (CNTB) will report earnings on 2026-05-18.

What are the consensus estimates for CONNECT BIOPHARMA HOLDINGS L (CNTB) next earnings?

The consensus EPS estimate for the next earnings of CONNECT BIOPHARMA HOLDINGS L (CNTB) is -1.44 USD and the consensus revenue estimate is 0 USD.

Can you provide the analyst count for CONNECT BIOPHARMA HOLDINGS L stock?

The number of analysts covering CONNECT BIOPHARMA HOLDINGS L (CNTB) is 11.